Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $1,316,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.16, for a total value of $1,316,000.00. Following the completion of the sale, the insider now owns 1,148,499 shares of the company’s stock, valued at $15,114,246.84. The trade was a 8.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $11.90 on Friday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -23.33 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a one year low of $5.02 and a one year high of $18.51. The company’s fifty day moving average price is $14.62 and its two-hundred day moving average price is $12.34.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SPRY shares. Leerink Partners increased their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $24.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $30,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of ARS Pharmaceuticals in the second quarter valued at about $87,000. Quarry LP acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $174,000. Finally, TFG Advisers LLC acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $180,000. 68.16% of the stock is owned by institutional investors and hedge funds.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.